Global Hematology Diagnostic Devices And Equipment Market

The hematology analyzers and reagents market consists of sales of hematology analyzers and reagents. Hematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in hematology analyzers and reagents are hematology analyzers, hemostasis analyzers, plasma protein analyzers, hemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and hematology stains. The hematology analysers are devices that measure the concentration of hemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialized research institutes, hospitals, specialized diagnostic centers, and others. The global hematology analyzers and reagents market size is expected to grow from $3.68 billion in 2021 to $4.14 billion in 2022 at a compound annual growth rate (CAGR) of 12.4%. The global hematology analyzer and reagent market is expected to grow to $5.25 billion in 2026 at a CAGR of 6.1%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In January 2019, Luminex Corporation acquired the flow cytometry portfolio of EMD MilliporeSigma for $75 million. EMD Millipore Corporation supplies tools for biotechnology, life science, and pharmaceutical industries. It was founded in 1954 and headquartered in Massachusetts, USA. Major players in the hematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. The regions covered in the global hematology analyzers and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global hematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Application: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Others 3) By End-User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Others

The apheresis consumables and equipment market consist of sales of apheresis consumables and equipment and related services. Apheresis is a medical technology in which the blood drawn from a donor is separated into its components through plasma exchange, stem cell harvest, photopheresis, and low-density lipid removal techniques. Further, the required components like plasma or platelets are retained and the remaining is passed to the circulation. The main products of apheresis consumables and equipment are disposables and devices. The apheresis consumables are the products that are used in apheresis technology. The technologies involved in disposables and devices are centrifugation and membrane filtration and procedures involved are photopheresis, plasmapheresis, LDL apheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others. The apheresis consumables and equipment are used in applications such as renal disease, neurology, hematology, and others. The global apheresis consumables and equipment market size is expected to grow from $2.39 billion in 2021 to $2.65 billion in 2022 at a compound annual growth rate (CAGR) of 10.9%. The global apheresis equipment market size is expected to grow to $4.16 billion in 2026 at a CAGR of 11.9%. The cases of blood disorders are on the rise globally, creating a need for blood transfusions. Apheresis Equipment helps to transfuse blood for blood disorders like sickle cell anemia, leukemia, and cancer. According to a report published by Leukemia and Lymphoma Society, 60,300 people in the USA are expected to be diagnosed with leukemia, and one person is diagnosed with blood cancer every 3 minutes requiring an immediate blood transfusion. According to the American Society of Hematology, 100,000 Americans possessed sickle cell Anemia and another 2 million people carry the trait requiring Apheresis Equipment for blood transfusion. According to the International Agency for Research on Cancer (IARC), by 2040, 16.3 million new cancer cases are expected to be reported worldwide. Cancer treatment requires at least 8 units of blood per patient per procedure, thus requiring blood component collection and blood transfusion. Thus, such a high prevalence of these blood disorders increases demand for apheresis consumables and equipment. Lack of awareness about apheresis consumables and equipment restrains the apheresis consumables and equipment market. Patients in developing countries like Africa. and Middle East are unaware of apheresis consumables and equipment and how the device can be advantageous to treat blood disorders and few lack access to the device at the medical facility due to high cost or unavailability. According to the journal of clinical apheresis, only Nigeria in the whole of West Africa. uses apheresis equipment to collect platelets. Most countries are unaware of the use of apheresis, leading to low demand for apheresis consumables and equipment, hindering the growth of the market. Companies are developing technologically advanced and automated products that enhance the efficiency of the product (blood). Technologically advanced products like automatic apheresis equipment with continuous flow centrifugation, automated interface system, and customized anticoagulant infusion system are being developed and adopted. The adoption of automated Apheresis equipment has resulted in a more efficient and rapid blood separation process. For instance, Companies like Haemonetics Corp have developed automated apheresis equipment NexSys PCS that increases productivity and improves quality and compliance in plasma collection centers. Major players in the apheresis consumables and equipment market are Asahi Kasei Medical, Haemonetics Corporation, Kawasumi Laboratories Inc, Fresenius SE & Co. KGaA, Terumo BCT, FenwalInc, Braun Melsungen AG, TherakosInc, HemaCare Corporation, and Cerus Corporation. The regions covered in the global apheresis consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the apheresis consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global apheresis consumables and equipment market is segmented - 1) By Product: Disposables, Devices 2) By Technology: Centrifugation, Membrane Filtration 3) By Application: Renal Disease, Neurology, Hematology, Others 4) By Procedure: Photopheresis, Plasmapheresis, LDL Apheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, Others

The cell culture consumables and equipment global market consist of sales of cell culture consumables, equipment, and related service. The services include only installation and maintenance services offered by equipment manufacturers. Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuges and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global cell culture consumables and equipment market size is expected to grow from $9.86 billion in 2021 to $10.99 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The global cell culture equipment market is expected to grow to $16.05 billion in 2026 at a CAGR of 9.9%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. Visikol launched OpenLiver 3D cell culture models in January 2019 to enter into 3D cell culture technology. FDA regulates the cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment FDA states that if the equipment is not labeled or mentioned as sterile, it would be removed from good manufacturing practices of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. Thermo Fisher acquired Brammer Bio for $1.7 billion in March 2019. Brammer Bio is a contract development and manufacturing organization (CDMO) for cell and gene treatment-centered biotechs. This transaction will strengthen Thermo Fisher to grow faster and expand the cell culture market in other countries. Brammer Bio is formed through the merger of Florida Biologix and Brammer Biopharmaceuticals and is headquartered in Cambridge, MA. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. The regions covered in the global cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cell culture consumables and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell culture consumables and equipment market is segmented - 1) By Product: Consumables, Instruments 2) By End-User: Industrial, Biotechnology, Agriculture, Others 3) By Application: Vaccination, Toxicity Testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem Cell Technology, Regenerative Medicine, Others 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services. Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics. In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor. The main types of flow cytometry are instruments, reagents and consumables, software, accessories, and services. Flow cytometry services include experimental design, specimen processing, acquisition and data analysis to support researchers, biotech and pharmaceutical companies in the process of drug development. The various technologies involved are cell-based, bead-based that are used in oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. The different end-users include hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, and other end users. The global flow cytometry market size is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The flow cytometry market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. Flow cytometry uses light scattering to determine the identity of cells. These cells are given certain markers called CDs (Clusters of Differentiation), based on the type of scattering. For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing. The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. In ELISA, colour changes in reagents are used to detect problematic cells. While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput. High-throughput flow cytometry is an emerging trend in the flow cytometry market. This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. Traditional cytometry methods are very slow, especially when several cells need to be tested within a day. Using high-throughput flow cytometry methods such as Fluorescence-Activated Cell-Sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time. Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis. The US FDA's Code of Federal Regulations (CFR) includes regulations related to a flow cytometry device called the Automated Differential Cell Counter (ADCC). An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts. This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used. Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices. Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC. In February 2019, Danaher acquired the biopharma business of GE Life Sciences for $21.4 billion. This acquisition will help Danaher to improve its existing bioprocessing capabilities. The biopharma division of GE Life Sciences is involved in the development and production of biologic drugs, vaccines and cell therapies. It develops products and solutions that facilitate research into fundamental cell and protein biology. GE Life Sciences is a division of GE Healthcare, which was founded in 1994 and has its headquarters in Illinois, the USA. Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher, Luminex, Miltenyi Biotec, Becton Dickinson and Company, Sysmex, Merck KGAA, Danaher Corporation, Apogee, Stratedigm, General Electric Company, EMD Millipore, Affymetrix, Biomérieux S.A., Cytonome St, Enzo Life Sciences, Enzo Biochem, Sony Biotechnology, Sysmex Partec, Life Technologies, BD, ACEA BIO, and TAKARA BIO The regions covered in the flow cytometry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the flow cytometry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global flow cytometry market is segmented - 1) By Type: Instruments, Reagents and Consumables, Software, Accessories, Services 2) By Technology: Cell-Based, Bead-Based 3) By End User: Hospitals and Clinics, Academia and Research Institutes, Pharmaceutical and Biotechnology Companies, Other End Users 4) By Application: Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology

The blood and blood components market consist of sales of blood and blood component. The market involves collection of donor's blood and segregating it into required components for the purpose of therapy. The main types of products in blood and blood components are whole blood and blood components. Human blood from a typical blood donation is known as whole blood. It is utilized in the treatment of excessive bleeding, exchange transfusions, and self-donation of blood. The different blood components include red blood cells, platelets, plasma, white blood cells and are used in anemia, trauma and surgery, cancer treatment, and bleeding disorders. The several end-users involved are hospitals, ambulatory surgical centers and others. The global blood and blood components market size is expected to grow from $35.63 billion in 2021 to $37.18 billion in 2022 at a compound annual growth rate (CAGR) of 4.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The blood and blood components market is expected to reach $44.11 billion in 2026 at a CAGR of 4.4%. The blood and blood components market is being driven by increasing incidence of trauma and road accidents. Sometimes, because of traumas such as hemorrhage, the volume of blood is reduced to a very low level and cannot be replaced fast enough by the body. Also, road accidents cause excessive blood loss from the body that has to be restored immediately. At times, the blood itself lacks a few components as in the case of hemophilia. All these conditions demand transfusion of blood and blood components into the patient's body. The growing prevalence of diseases and increasing numbers of road accidents and traumas are increasing the demand for blood and thus driving the market. According to a report by Centers for Disease Control and Prevention, Hemophilia A affects one out of every 5,000 male babies born. Every year, about 400 newborns are born with haemophilia A. Also, as per US NIH data, in 2019, traumatic injury was found to be the foremost reason of mortality among 1-40 years old people. The blood and blood components market is restrained by the growing risk of developing or transferring an infection while the blood is transmitted to the patients. The growing possibilities of developing any Transfusion Transmitted Infection (TTI) is imposing a restriction on the growth of the market. The fear of transfusion of diseases from the donor to the recipient, forces many customers to avoid using donated blood, thus hampering the growth of the blood and blood components market. The most common viral agents that can be transmitted through blood transfusion are Human Immunodeficiency Virus (HIV), Hepatitis Viruses, West Nile Virus (WNV), Human T-cell Lymphotrophic Viruses (HTLVs). The most prominent trend that has been witnessed in the blood and blood components market is the growing number of collaborations between the players involved in the market. Companies are adopting partnerships and collaborations in order to expand their reach, increase customer base and generate awareness in the market. For example, the American Red Cross collaborated with HealthStream with an aim of introducing new program for healthcare organizations. Similarly, the BloodCenter of Wisconsin collaborated with SysLogic Inc., to study how the RFID technology can be used to enhance safety of the patient while collecting and transfusing blood products. The blood and blood components market in European Union is governed by Directive 2002/98/EC of the EU regulations. The regulatory body engages itself in providing guidelines and setting standards for quality and safety of collection, testing, processing, storage, and distribution of blood and blood components. These guidelines ensure greater quality and safety of whole blood and its components to prevent transmission of diseases and also highlight necessary measures for their collection and distribution. In March 2019, Grifols SA, Barcelona-based company acquired a 26% stake in Shanghai RAAS Products Co., Ltd. for $1.9 billion. As per the agreement, Grifols agreed to share its technological know-how and engineering services with Shanghai RAAS. The acquisition was undertaken to manufacture, commercialize and develop plasma products and transfusion diagnostic solutions in China. Shanghai RAAS Products Co., Ltd. is a China-based company that is primarily engaged in the research and development, manufacture and distribution of blood products. Major players in the blood and blood components market are American Red Cross, Australian Red Cross Blood Service, Abbott Laboratories, Blood Centers of America, Becton, Dickinson & Co., German Red Cross, Nipro Medical Corporation, American Association of Blood Banks, AVIS National and National Blood Authority Australia. The regions covered in the blood and blood components market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the blood and blood components market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global blood and blood components market is segmented - 1) By Product: Whole Blood, Blood Components 2) By End-User: Hospitals, Ambulatory Surgical Centers, Others 3) By Application: Anemia, Trauma and Surgery, Cancer Treatment, Bleeding Disorders 4) By Blood Components: Red Blood Cells, Platelets, Plasma, White Blood Cells

The cell based assays market consists of sales of cell based assays. Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function. Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others. The main product and services of cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted throughout their use. The various instruments used are microplates, microplate readers, high throughput screening, and liquid handling systems and different consumables include reagents and media, cells and cell lines, probes and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, others and are applied for drug discovery, basic research, ADME studies, predictive toxicology, others. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, Contract Research Organizations (CRO) and others The global cell based assays market size is expected to grow from $20.73 billion in 2021 to $22.58 billion in 2022 at a compound annual growth rate (CAGR) of 9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell based assays market is expected to reach $31.87 billion in 2026 at a CAGR of 9%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of Investigational New Drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (High Content Analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In April 2019, PerkinElmer, a global corporation for diagnostics, life science research, food, environmental and industrial testing acquired Cisbio Bioassays for an undisclosed amount. The acquisition expands PerkinElmer's R&D capability in cell based assay, and customer base in key growth geographies including the Americas, Europe, and China in order to expand its market reach for reagents. Cisbio Bioassays is a custom assay service provider based in Codolet, France and was founded in 1974. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell based assays market is segmented - 1) By Product and Service: Consumables, Instruments, Services, Software  2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Others 3) By End User: Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Others 5) By Consumables: Reagents and Media, Cells and Cell Lines, Probes and Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The allergy diagnostics market consists of sales of allergy diagnostics solutions by entities (organizations, sole traders, and partnerships) that are used to identify the allergen (substance causing allergic reaction) in a human body. An allergy is a reaction of the immune system to an allergen that isn't normally detrimental to the human body. Allergens are foreign substances that cause allergic reactions. Certain food like peanut, milk, egg and wheat, pollen, and pet dander are a few examples of allergens. Allergy diagnostics is a procedure used by a qualified allergy specialist to evaluate if the body is allergic to a certain substance. A blood test, a skin test, or an elimination diet can be used as part of the examination. The diagnostic procedure for allergies depends on the type of allergens and the mode of transmission. The main types of allergy diagnostics tests are in-vivo allergy tests and in-vitro allergy tests. In-vivo allergy tests are performed on the human body to identify the cause of the allergic reaction. In-vitro allergy tests are performed on laboratories using test tubes and Petri dishes to identify the allergy causing substance. The main products in allergy diagnostics include consumables, instruments, and luminometers. By allergens, the allergy diagnostics market is segmented into inhaled allergens, food allergens, and drug allergens. Major end-users of allergy diagnostics include diagnostic laboratories, hospital-based laboratories, and academic and research institutes. The global allergy diagnostics market size is expected to grow from $4.62 billion in 2021 to $5.07 billion in 2022 at a compound annual growth rate (CAGR) of 9.78%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The allergy diagnostic market is expected to reach $7.50 billion in 2026 at a CAGR of 10.30%. The increased occurrences of allergic diseases will propel the growth of the allergy diagnostics market. The rise in allergy diseases has been attributed to increased environmental pollution from traffic and numerous industries. An allergic reaction is described as an abnormal immune system response to an allergen. Allergy diseases include anaphylaxis, allergic rhinitis (often referred to as "hay fever"), food allergies, skin allergies, and allergic asthma. Avoiding allergen is the most essential treatment for allergic disorders. As a result, proper allergy diagnosis is crucial for effective allergy treatment. For instance, according to the community-based EuroPrevall survey report, in 2019, the prevalence of probable food allergy in adults was 0.3%, 1.4%, 2.1%, 2.8%, 3.3%, and 5.6% in Athens, Reykjavik, Utrecht, Lodz, Madrid, and Zurich in 2019. The most common allergy symptoms were oral allergy symptoms (81.6%), followed by skin allergy symptoms (38.2%), and rhinoconjunctivitis (29.5%). Thus, the rise in the prevalence of allergic diseases will further support the growth of the allergic diagnostics market. The rise in the number of collaborations and partnerships among companies operating in the allergy diagnostics industry to invent new testing methods or improve existing ones is a recent trend in the market. For instance, in July 2019, PerkinElmer, Inc. and EverlyWell, Inc. announced a new partnership to accelerate innovation and accessibility of consumer-initiated health testing by bringing PerkinElmer's CLIA-certified and CAP-accredited lab facilities into EverlyWell's network of lab providers. PerkinElmer supplies the knowledge behind EverlyWell's panels for Lyme disease and food sensitivity testing, which are the first products to emerge from this collaboration. Both tests use dried blood spot testing, which has been used by doctors and hospitals for decades to identify disease biomarkers with just a few drops of blood. They were developed by board-certified medical geneticists at PerkinElmer Genomics and validated on the EUROIMMUN EUROBlotOne® and EUROIMMUN AnalyzerTM systems. In October 2021, IMA Group, a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic, announced the acquisition of Diagnostics Research Group for an undisclosed amount. The acquisition provided IMA access to a wider range of patient populations and allows it to expand into the southwest United States. It also expands IMA's Clinical Research Division and its network of over 90 physical medical offices. Diagnostics Research Group (DXRG) is a clinical research site based in San Antonio, Texas, with expertise in vaccine and medical device development, internal medicine, allergies, and pulmonary and fatty liver diseases. Major players in the allergy diagnostics market are BioMerieux SA, Danaher Corporation, HOB Biotech Group Corp. Ltd, HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group Plc, Siemens Healthineers AG, Thermo Fischer Scientific Inc, PerkinElmer Inc. (Euroimmun AG), R-Biopharm AG, Alcon Laboratories, Inc., Abbott Laboratories, HollisterStier Allergy, NEOGEN Corporation, AESKU.GROUP GmbH, ACON Laboratories, Erba Group, and Astra Biotech GmbH. North America was the largest region in the allergy diagnostics market in 2021. The regions covered in the allergy diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allergy diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global allergy diagnostics market is segmented - 1) By Test Type: In-Vivo Allergy Tests, In-Vitro Allergy Tests 2) By Allergen: Inhaled Allergens, Food Allergens, Drug Allergens 3) By Products: Consumables, Instruments, Luminometers 4) By End-User: Diagnostics Laboratories, Hospital-Based Laboratories, Academic and Research Institutes